NCT03844568

Brief Summary

Numerous elderly patients are suffering from aspiration pneumonia due to anatomical or functional predisposing factors including enteral tube feeding, swallowing difficulties, and gastroesophageal reflux disease (GERD). Previous studies have been demonstrated that continuous positive airway pressure (CPAP) is an acceptable means of managing chronic aspiration, atelectasis, and GERD. The purpose of this study is to determine whether nocturnal nasal CPAP is beneficial in patients with aspiration pneumonia and that it would contribute to the rapid clinical stability of aspiration pneumonia.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 18, 2019

Completed
28 days until next milestone

Study Start

First participant enrolled

March 18, 2019

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 8, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 8, 2021

Completed
Last Updated

April 12, 2023

Status Verified

April 1, 2023

Enrollment Period

1.9 years

First QC Date

February 15, 2019

Last Update Submit

April 10, 2023

Conditions

Keywords

aspiration pneumoniacontinuous positive airway pressure, CPAP

Outcome Measures

Primary Outcomes (1)

  • Time to clinical stability-respiration (CS-r)

    time to respiratory stabilization (respiratory rate ≤ 24/min and arterial oxygen saturation ≥ 90% or a partial pressure of oxygen ≥ 60mmHg on room air or usual requirement level)

    up to 2 weeks

Secondary Outcomes (8)

  • Time to clinical stability

    up to 2 weeks

  • Early clinical stability rate

    3 days

  • Late clinical stability rate

    7 days

  • Hospital length of stay

    1 day (during hospital admission)

  • Radiological improvement

    3 and 7 days

  • +3 more secondary outcomes

Study Arms (2)

nasal CPAP group

EXPERIMENTAL

Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment

Device: nocturnal nasal continuous positive airway pressure

Control group

NO INTERVENTION

Usual pneumonia treatment

Interventions

applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime

nasal CPAP group

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Age ≥ 65 years
  • Diagnosis of pneumonia: the presence of new pulmonary infiltration in dependent areas on chest radiographs at the time of hospitalization with at least one of the following
  • New or increased cough
  • Abnormal temperature (\< 35.6℃ or \> 37.8℃)
  • Abnormal serum leukocyte count (leukocytosis, left shift, or leukopenia)
  • Aspiration tendency or risk factors for frequent or large volume aspiration with at least one of the following
  • Altered mental status
  • Gastrointestinal disorder
  • Dysphagia or swallowing difficulties
  • Esophageal motility disorders
  • Tracheostomy state
  • Enteral tube feeding
  • Informed consent

You may not qualify if:

  • Severe hypercapnia (PaCO2 \> 70mmHg)
  • Respiratory arrest requiring tracheal intubation
  • Cardiac arrest, acute coronary syndrome or life threatening arrhythmias
  • Failure of more than two organs
  • Recent trauma or burns of the neck and face
  • Non- cooperation
  • Pregnancy
  • Withdrawal of consent
  • Refusal of treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

Location

MeSH Terms

Conditions

Pneumonia, AspirationMicrocephaly, Primary Autosomal Recessive, 6

Condition Hierarchy (Ancestors)

PneumoniaRespiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Eun Sun Kim, MD

    Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

February 15, 2019

First Posted

February 18, 2019

Study Start

March 18, 2019

Primary Completion

February 8, 2021

Study Completion

February 8, 2021

Last Updated

April 12, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations